


## **CLAIM AMENDMENTS**

This listing of claims will replace all prior versions and listings of claims in the application:

**1.-30.** (canceled)

**31.** (currently amended) A device for transdermal delivery ~~of~~ comprising a compound of the following Formula I:



wherein A is hydrogen or deuterium, R is C<sub>1-6</sub>-alkyl, C<sub>3-10</sub>-cycloalkyl or phenyl, which may each be substituted with C<sub>1-3</sub>-alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium and where the C-atom marked with a star "\*" is present in the (R)-configuration, and the compound of Formula I is present in a polymer matrix and can be released through the human skin in a dose of 0.5-20 mg per day.

**32.** (previously presented) A device of claim 31 wherein the device is produced by a process comprising adding a compound of Formula I in free base form to the polymer matrix.

**33.** (previously presented) A device of claim 31 wherein the polymer matrix incorporates 55-90 percent by weight of a contact adhesive and is self-adhesive.

**34.** (previously presented) A device of claim 31 wherein the polymer matrix incorporates one or more contact adhesives which are chosen from acrylates, ethylene vinyl acetates (EVA), silicones or styrene block copolymers (SXS).

**35.** (previously presented) A device of claim 31 wherein the polymer matrix comprises up to 50-95 percent by weight of a hot-melttable mixture of a silicone based contact adhesive and at least one softener.

**36.** (previously presented) A device according to claim 31 wherein the polymer matrix comprises up to 50-95 percent by weight from (a) a hydrophilic contact adhesive and/or (b) a mixture of a hydrophobic contact adhesive with 2-20 percent by weight, based on the total weight of the polymer matrix, of a hydrophilic polymer and/or (c) a mixture of a hydrophilic with a hydrophobic contact adhesive.

**37.** (previously presented) A device according to claim 36 whereby the hydrophilic polymer is PEO, PVP or PVAc.

**38.** (previously presented) A device of claim 31 wherein R is methyl, ethyl, isopropyl, 1-propyl, 1-butyl, 2-butyl, tertiary-butyl, iso-butyl, pentyl or hexyl.

**39.** (previously presented) A device of claim 31 wherein the compound is (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate (fesoterodine).

**40.** (previously presented) A device of claim 31 wherein the compound of the Formula I has been introduced into the polymer matrix in a degree of purity of above 97 percent by weight.

**41.** (previously presented) A device of claim 31 wherein the device:

- (a) exhibits a surface of a maximum 50 cm<sup>2</sup>;
- (b) comprises a self-adhesive polymer layer, which
  - (b1) exhibits a weight of 30-300 g/m<sup>2</sup>,
  - (b2) contains 50-95% by weight of a contact adhesive,
  - (b3) contains a compound of Formula I in a concentration of 5-40 percent by weight based on the total weight of the polymer matrix; and
- (c) delivers the compound Formula I with a steady flux rate of at least 4 µg/cm<sup>2</sup>/hour through the human skin over a time period of at least 24 hours.

**42.** (previously presented) A device of claim 31 wherein the device exhibits a base area of a maximum of 40 cm, and the loading of the active ingredient of the self-adhesive polymer matrix amounts to 7-30 percent by weight.

**43.** (previously presented) A device of claim 31 wherein the device can transport a compound of the general Formula I in a dose of at least 3 mg per day over at least 24 hours at a constant flux rate through the human skin.

**44.** (previously presented) A device of claim 31 wherein the device comprises an adhesive matrix containing an active ingredient (1), a backing being impermeable and inert for the constituents of the adhesive matrix (2), and a protective layer detachable immediately before use (3).

**45.** (currently amended) A device for the transdermal delivery of the free base of (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate over a time period of at least 24 hours at a constant flux rate of at least  $4 \mu\text{g}/\text{cm}^2/\text{hour}$ , wherein said device comprises the free base of (R)-2-[3-(1,1-diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl isobutyrate.

**46.-67.** (canceled)

**68.** (previously presented) A device of claim 31 wherein the device is a flat-shaped device for transdermal delivery of the matrix type where the compound of Formula I is present in a polymer layer or polymer paste.